is a carrier there can be no stigma. Most couples would prefer to know before conception if both partners carry the same gene defect. Few have difficulty accommodating the need to care for the sick who exist while taking steps to avoid recurrence. The minority who chose to continue to term would need support. Nevertheless, experience shows that, in Britain at least, most couples would opt for a healthy child.
In short, the capacity to screen for carriers of cystic fibrosis is set eventually to carry genetics if not into every living room, at least into every health centre. For it is there that most people would prefer to have such investigations.4 Is it now time to start the general introduction of genetic screening? The two studies reported in this issue explore the options and illustrate many of the problems.
The paper by Bekker and colleagues introduced a member of the research team to a London practice (p 1584).5 A lack of interest in carrier testing emerges, which is perhaps unsurprising: an inner city practice will always be a tough test of any preventive programme. The authors found that the only effective screening option in terms of uptake was to collect samples opportunistically, a similar finding to that reported by Watson et al. 6 Although the authors feared that this might reflect inappropriate "selling" of the test, it seems at least as likely that people will not inconvenience themselves for a test that they do not think they need. People without a family history "feel lucky."
Harris and colleagues got general practitioners in several practices to target the first antenatal visit (p 1580 Introducing carrier screening to senior school students and linking it to a health education programme" is a possible "turnstile" for the future. Our first need is to educate the health care professionals. At the end of this decade couples will want to know which recessive genes they carry. If they don't get the answer they will at least expect their doctor to understand the question.
Carrier testing cannot easily be blocked by purely economic arguments as the fall in health costs from fewer children born with cystic fibrosis would more than offset the cost of screening.' It seems set to come into wider use with the usual debate over resources, cost-benefit analysis, public understanding, the changing clinical burden, and the ethics of termination. It Several factors prevail in Britain that will preserve the status quo. Firstly, the rate at which new patients with end stage renal failure are accepted for dialysis has increased to an average of 60 per million each year,' with some regions exceeding 80 patients per million-the current target based on studies of incidence.8 Any increase in the rate of acceptance for dialysis (which is both justifiable and desirable) would therefore have considerable resource implications with increasing need for maintenance haemodialysis-a commodity likely to remain in short supply. Secondly, with the internal market, price will emerge as the main factor in deciding between similar treatments.
Contracts for continuous ambulatory peritoneal dialysis should specify standards of care and staffing requirements.9 They should include technological advances that are expensive but of proved value (such as disconnect systems that reduce peritonitis,'0 physiological dialysis fluids," and automated dialysis techniques); the care of high risk patients; and the need to provide increased haemodialysis and ward back up.5 All these factors reduce the difference in cost between continuous ambulatory peritoneal dialysis and haemodialysis.
Currently evolving practice, though still in its infancy, suggests that purchasers may be attracted to the cheaper peritoneal dialysis even when adequately informed of the choices. One way to tackle the increasing financial burden of renal dialysis (and the limited budgets of renal units) is for units to share costs with general practitioners (through their prescribing budgets). About half of current patients' costs are met this way, although this practice is much more expensive (because of the need for dispensing fees and the absence of discounts for bulk purchases).
The future of the renal services ultimately rests with the purchasers; herein lies the chance to reform the service to the overall advantage of patients. This will only happen if money follows the patients, whose referrals continue.
